# LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE
> **NDA202171** · New Drug Application · Sponsor: MATRIX LABS LTD · Approved 2011-09-08
## Drug
- **FDA Application Number:** NDA202171
- **Application type:** New Drug Application
- **Brand name:** LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE
- **Generic name:** Lamivudine
- **Active ingredients:** LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** MATRIX LABS LTD
- **First approval:** 2011-09-08
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202171)
---
*AI Analytics · CC0 1.0*